Renovorx reports third quarter 2023 financial results and operational highlights

Los altos, calif.--(business wire)--renovorx, inc. (“renovorx” or the “company”) (nasdaq: rnxt), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced financial results for the third quarter ended september 30, 2023. “we remain focused on our core mission to improve the lives of patients diagnosed with difficult-to-treat cancers by delivering novel targeted combination therapies that have the potential to alter the current paradigm of oncology car.
RNXT Ratings Summary
RNXT Quant Ranking